Equities

SyntheticMR AB (publ)

SyntheticMR AB (publ)

Actions
  • Price (SEK)27.40
  • Today's Change-0.600 / -2.14%
  • Shares traded10.73k
  • 1 Year change-14.91%
  • Beta--
Data delayed at least 15 minutes, as of Apr 30 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SyntheticMR AB (publ) is a Sweden-based company that develops and markets software solutions for Magnetic Resonance Imaging (MRI). The Company provides SyMRI, which measures the absolute properties of the brain and delivers adjustable contrast images, automatic biomarker segmentation and quantitative data in a single MR scan. The SyMRI product is available in different packages. SyMRI IMAGE provides fast MRI workflows, allowing high patient throughput. SyMRI NEURO enables automatic segmentation of brain tissue, providing objective decision support. SyMRI Research Edition includes exportable SyMaps, parametric common contrast weighted images and maps of the brain, allowing the investigation to be taken even further. SyMRI is a registered trademark in Europe and in the USA.

  • Revenue in SEK (TTM)89.21m
  • Net income in SEK10.01m
  • Incorporated2007
  • Employees37.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Alligator Bioscience AB58.11m-248.59m682.24m58.00--50.02--11.74-0.5613-0.56130.12050.0180.4035--8.341,001,845.00-172.61-73.26-399.57-91.33-----427.81-811.68----0.5759--62.7816.60-28.53---20.34--
Intellego Technologies AB186.49m59.61m772.13m68.0012.395.1112.234.142.362.367.435.740.88413.263.692,742,544.0028.26--44.00--68.73--31.96--1.975.820.1684--222.74--493.56------
BioPorto A/S48.59m-88.42m775.94m31.00--8.22--15.97-0.1605-0.16050.08830.15850.3123.4011.96998,645.20-56.77-71.10-79.27-96.5565.1963.38-181.95-239.223.09-1,718.970.1076--6.873.5425.81---51.56--
Nightingale Health Oyj42.77m-211.39m822.07m81.00--1.20--19.22-0.2979-0.29790.06031.500.03441.603.8744,560.98-17.02-14.20-18.12-15.6975.8183.57-494.25-408.5014.15--0.0378--80.8019.05-12.38------
Moberg Pharma AB (publ)0.00-21.09m969.83m----1.56-----1.20-1.200.0021.840.00-------3.52---3.66----------3.04--0.0077---100.00---34.26------
XSpray Pharma AB (publ)0.00-179.67m1.01bn26.00--1.83-----7.02-7.020.0022.190.00----0.00-26.60-18.38-28.03-19.26--------4.36--0.0504-------36.45--2.87--
Vistin Pharma ASA433.83m55.65m1.03bn77.0018.533.5114.072.381.271.279.886.701.112.317.445,692,663.0014.281.7318.932.1159.9358.9212.832.360.853632.960.0934--51.3516.951,066.84---0.1922--
Cereno Scientific AB0.00-48.11m1.08bn5.00--4.16-----0.241-0.2410.000.92580.00----0.00-19.22-16.81-20.75-18.26-----------12.920.1734-------73.95--44.79--
Diamyd Medical AB282.00k-120.18m1.08bn26.00--5.60--3,841.28-1.41-1.410.00331.910.0014--6.5611,280.00-59.77-25.46-66.19-28.37-4,930.85-1,419.23-42,617.73-5,896.43---130.780.1176--20.26-5.54-12.13------
SyntheticMR AB (publ)89.21m10.01m1.14bn37.00112.079.7970.2712.800.24450.24452.172.800.6599--1.612,411,162.007.417.198.898.85105.78106.7411.229.08--14.130.010721.5030.6713.0570.34-7.3326.79--
Infant Bacterial Therapeutics AB0.00-123.07m1.15bn8.00--3.89-----9.90-9.900.0022.650.00----0.00-35.11-16.11-38.65-16.69------------0.00-------88.03------
Arcticzymes Technologies ASA117.72m18.53m1.30bn61.0069.974.2752.4811.080.37020.37022.356.070.36180.59412.43--5.6915.526.1217.1695.0296.6915.7433.1012.43--0.0392---13.1612.24-43.02--47.93--
Photocure ASA495.51m264.26k1.48bn106.007,701.953.1153.643.000.00720.007218.5817.790.70010.82039.37--0.0375-3.090.0429-3.5694.7893.640.0535-5.194.32--0.00--27.3522.50100.37--49.83--
Hansa Biopharma AB165.88m-844.88m1.52bn166.00------9.19-16.07-16.073.15-7.100.142464.031.86987,386.90-72.51-47.96-92.27-56.1256.8064.18-509.33-835.042.55-9.651.65---13.22109.06-36.09---35.24--
Devyser Diagnostics AB169.30m-53.60m1.61bn118.00--4.18--9.50-3.31-3.3110.4623.650.3351.595.531,434,746.00-10.65-8.97-12.00-10.1585.5380.14-31.78-23.915.11--0.1626--33.7128.59-16.64--44.59--
Data as of Apr 30 2024. Currency figures normalised to SyntheticMR AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

20.36%Per cent of shares held by top holders
HolderShares% Held
Handelsbanken Fonder ABas of 31 Mar 20242.20m5.27%
Swedbank Robur Fonder ABas of 29 Feb 20242.03m4.88%
Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 31 Dec 20221.87m4.49%
Aktia Fondbolag Abas of 28 Mar 2024915.34k2.20%
Aktia Bank Plc (Investment Management)as of 31 Dec 2022915.34k2.20%
Fondita Fund Management Co. Ltd.as of 31 Mar 2024500.00k1.20%
Axxion SA (Luxembourg)as of 29 Feb 202451.85k0.12%
AIFM Capital ABas of 31 Dec 20211.07k0.00%
More ▼
Data from 31 Dec 2021 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.